GLP-1 medications now account for 11.4 percent of annual pharmacy claims among employers offering the drugs, up sharply from 6.9 percent in 2023.
That single statistic captures why weight-loss benefit design has become one of the most closely watched line items in employer health planning, a category that barely registered in benefits budgets five years ago and now competes for attention with specialty drug spend broadly.
The Coverage Landscape Right Now
Employer coverage of GLP-1 medications remains split and cautious rather than broad-based. Sixty percent of employers currently provide coverage for diabetes indications only, a share that has actually risen from 55 percent the prior year as some employers narrow eligibility rather than expand it. Thirty-six percent extend coverage to both diabetes and weight-loss indications, while 45 percent cover GLP-1 drugs for other FDA-approved conditions such as sleep apnea and cardiovascular disease. Among larger employers specifically, coverage has moved faster, with 43 percent of firms with more than 5,000 workers covering GLP-1 medications for obesity as of the most recent data, up from just 28 percent the year before.
Cost remains the dominant constraint shaping these decisions. With GLP-1 claims nearly doubling their share of total pharmacy spend in three years, employers are treating weight-loss drug coverage as a budget-line decision as much as a benefits-design one, weighing per-employee monthly cost against projected downstream savings from reduced diabetes, cardiovascular, and musculoskeletal claims.
What Employers Are Actually Covering
Wraparound Support Services
Rather than covering GLP-1 prescriptions directly and universally, many employers are investing more heavily in the services that surround medication use. Seventy-four percent of employers offering diabetes and weight-loss benefits include disease or case management support, 61 percent include nutritional counseling, and another 61 percent cover bariatric surgery. This pattern suggests employers see medication coverage as one component within a broader weight-management benefit rather than a standalone line item.
Redirecting Access Rather than Paying Directly
A notable share of employers are managing GLP-1 demand by redirecting it elsewhere instead of adding it to the standard medical plan. Around 27 percent of employers actively encourage employees to access GLP-1 medications through a direct-to-consumer telehealth platform, while 21 percent are pushing employees toward using flexible spending accounts, health savings accounts, or integrated health reimbursement arrangement dollars to cover the cost themselves. This reflects a deliberate strategy of enabling access without absorbing the full claims cost on the group health plan.
Employee Demand Is Outpacing Coverage
The gap between what employees want and what plans currently offer is substantial. Sixty-five percent of employed adults say they would be more likely to use a GLP-1 medication if their employer covered at least part of the cost, a demand signal that HR and benefits teams are increasingly citing as pressure to expand coverage even as cost concerns push in the opposite direction.
How Direct-To-Consumer Access Fits the Employer Strategy
Given that more than a quarter of employers are already actively directing employees toward direct-to-consumer telehealth platforms as an access route, that channel has become a practical middle ground between full plan coverage and no support at all. Telehealth GLP-1 providers structured around FSA or HSA-eligible payment and physician-supervised prescribing fit naturally into this employer strategy, since they let an employer point employees toward a compliant access pathway without adding the medication to the group formulary. Telehealth weight-loss providers offer physician-supervised access to GLP-1 medications, representing the kind of independently accessed care option employers increasingly reference when steering employees toward self-funded or account-based payment routes rather than direct plan coverage.
Where the Friction Is
The core tension in employer-sponsored weight-loss benefits has not resolved: rising claims cost is pushing employers toward tighter eligibility criteria and utilization management, while employee demand and competitive pressure to offer attractive benefits push in the opposite direction. Some employers have responded by narrowing eligibility to specific BMI thresholds or requiring documented participation in complementary lifestyle programs before approving GLP-1 coverage, adding administrative complexity to what employees often expect to be a straightforward prescription benefit.
What’s Likely Next
Given that GLP-1 claims share has grown by more than four percentage points in three years with no clear sign of plateauing, expect continued experimentation with utilization management, tiered eligibility, and account-based cost-sharing structures rather than a swing toward universal coverage. The current split, roughly a third of employers covering weight loss outright, another chunk covering diabetes-only, and a meaningful minority actively redirecting employees to outside telehealth channels, looks likely to persist as the dominant pattern through the next benefits cycle rather than consolidate around one approach.
Conclusion
Employer-sponsored weight-loss benefits sit at the intersection of rising employee demand and rising claims cost, and the data shows employers responding with a patchwork of partial coverage, wraparound services, and redirected access rather than a single clear strategy. That patchwork is likely to define the category for the foreseeable future, as cost pressure and competitive benefits positioning continue to pull employer decisions in opposite directions.
